Q2 FY2026 EarningsQ2 FY2026 results significantly beat consensus on the top line, with net revenue of $0.62M exceeding expectations by 26.41%. While gross margins of 91.2% were slightly above the 90.0% consensus, net loss was narrower than expected at -$3.73M vs. -$3.86M. Commercial momentum for QUELIMMUNE remains strong with 82% YoY growth, although elevated R&D spending for adult AKI trials continues to drive operational losses.
Financial report interval: 2026.03.30 - 2026.06.30
Overview: SeaStar Medical(ICU) the Revenue is 615 K (+81.95%), Beat estimate;the EBIT is -3.791 M (-115.9%), Beat estimate;the EPS is -0.91 (+49.44%), Beat estimate.
Actual
YoY
Estimate
YoY
Vs estimate
YoY
RevenueExceed expectations
0.00B81.95%
0.00B43.93%
+0.00B38.02%
EBITExceed expectations
-0.00B115.89%
-0.00B120.07%
+0.00B4.18%
EPSExceed expectations
-0.9149.44%
-0.9746.11%
+0.06003.33%
Revenue
ActualEstimateUnit: USD
qf
EBIT
ActualEstimateUnit: USD
qf
Net income
ActualEstimateUnit: USD
qf
EPS
ActualEstimateUnit: USD
qf